✓ Translated by DotMD AI Clinical Council Source: Interdisciplinary cardiovascular and thoracic surgery • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #41689184 ↗

Phase III Randomized Trial: Does the Fissure Last Technique Really Reduce Postoperative Airleak After Lung Resection? Results From a Prospective Randomized Controlled Trial (N = 33)

Original Paper Title: “Does the Fissure Last Technique Really Reduce Postoperative Airleak After Lung Resection? Results From a Prospective Randomized Controlled Trial”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 33
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Results from this study suggest that the FL strategy does not confer any benefit in terms of PAL, even in the context of an incomplete fissure. Clinical registration number: n 184/2020, 5/11/2020, EudraCT2020-004900-33.
  • Study Design & Sample: Phase III Randomized Trial published in Interdisciplinary cardiovascular and thoracic surgery (N = 33 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Interdisciplinary cardiovascular and thoracic surgery (2026), this phase iii randomized trial evaluating 33 human participants investigated: The fissure last (FL) technique described in 1998 has the goal of minimizing postoperative airleak leaving the stapling of the fissure as the last step. Key clinical takeaway: Results from this study suggest that the FL strategy does not confer any benefit in terms of PAL, even in the context of an incomplete fissure. Clinical registration number: n 184/2020, 5/11/2020, EudraCT2020-004900-33.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Interdisciplinary cardiovascular and thoracic surgery, 2026-02-05; N = 33; Rigor 82/100): Results from this study suggest that the FL strategy does not confer any benefit in terms of PAL, even in the context of an incomplete fissure. Clinical registration number: n 184/2020, 5/11/2020, EudraCT2020-004900-33.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: chronic-obstructive-pulmonary-disease-with-acute-exacerbation → Condition: bronchiolitis-obliterans-and-bronchiolitis-obliterans-syndrome →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41689184: Phase III Randomized Trial: Does the Fissure Last Technique Really Reduce Postoperative Airleak After Lung Resection? Results From a Prospective Randomized Controlled Trial (N = 33)

3 of 3 Free Questions Remaining